Thomas C. Walter
Expertise in
15
conditions

Thomas C. Walter

Lyon, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
15
conditions
Lyon, FR 

Overview

Thomas Walter practices practicing medicine in Lyon, France.

Mr. Walter is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, VIPoma, Carcinoid Syndrome, Liver Embolization, and Hepato-Pancreato-Biliary Surgery.

He is actively involved in clinical research, co-authoring 260 peer reviewed articles and participating in 13 clinical trials.

Gender

Male

Locations

Lyon, France
Other Locations
Paris, 75006, France
Orsay, France
Villeurbanne, France
Fontainebleau, 77300, France
Villejuif, France
France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 07, 2025
Intervention Type: Drug, Combination product
Study Drugs: Nilotinib, Everolimus, Sorafenib, Lapatinib, Pazopanib, Olaparib, Durvalumab, Tremelimumab
Study Phase: Phase 2
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 15, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Paclitaxel
Study Phase: Phase 3
Randomized, Double-blind, Multicenter Placebo-controlled Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy
Randomized, Double-blind, Multicenter Placebo-controlled Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other
Study Phase: Not Applicable
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Drug, Other
Study Drugs: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) Peptide Receptor Radionuclide Therapy, CAPTEM (Capecitabine and Temozolomide), Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Study Phase: Phase 3
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Folfiri+Bevacizumab, Folfiri
Study Phase: Phase 2
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
View 8 Less Clinical Trials

260 Total Publications

Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours.
Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours.
Journal: Journal of neuroendocrinology
Published: February 01, 2026

Frequently Asked Questions about Thomas C. Walter

Is Thomas C. Walter a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas C. Walter is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas C. Walter participate in research or clinical trials?

Yes. Thomas C. Walter has published 260 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Thomas C. Walter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Walter's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 38 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile